Literature DB >> 1688956

Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo.

H N Keer1, J M Kozlowski, Y C Tsai, C Lee, R N McEwan, J T Grayhack.   

Abstract

Transferrin receptors (TfR) were measured in benign and malignant prostatic cells by performing Scatchard analysis following the administration of 125I-transferrin. Established human prostate cancer cell lines (PC-3 and DU-145) as well as biologically aggressive variants (PC-3 ASC and PC-3 DES) were shown to possess significant levels of high affinity TfR when assessed in vitro. In contrast, TfR content was negligible in cultured stromal cell fractions derived from human benign prostatic hyperplasia (BPH) specimens. Scatchard analysis was also performed on in vivo derived prostatic tissues: tumors resulting from the subcutaneous xenografting of PC-3 ASC cells into athymic, nude mice and fresh BPH surgical specimens. These tissues were dissociated and their stromal and epithelial components separated. TfR were only detected in the epithelial component of both malignant and benign epithelial cells. PC-3 ASC tumor cells exhibited TfR levels comparable to their in vitro expression and these levels were 10-fold greater than in the BPH cells. These findings suggest that elevated TfRs may serve as another useful marker of the transformed phenotype within human prostate tumor systems.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688956     DOI: 10.1016/s0022-5347(17)39970-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

1.  Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium.

Authors:  Sneha Sundaram; Shyamal K Roy; Balamurali K Ambati; Uday B Kompella
Journal:  FASEB J       Date:  2009-07-16       Impact factor: 5.191

2.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

3.  Selective stimulation of prostatic carcinoma cell proliferation by transferrin.

Authors:  M C Rossi; B R Zetter
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

4.  Cytotoxicity of a Ti(IV) compound is independent of serum proteins.

Authors:  Arthur D Tinoco; Horatio R Thomas; Christopher D Incarvito; Alan Saghatelian; Ann M Valentine
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

5.  Theranostic Polyaminocarboxylate-Cyanine-Transferrin Conjugate for Anticancer Therapy and Near-Infrared Optical Imaging.

Authors:  Chi Soo Kang; Siyuan Ren; Xiang Sun; Hyun-Soon Chong
Journal:  ChemMedChem       Date:  2016-09-14       Impact factor: 3.466

Review 6.  Use of liposomes as drug delivery vehicles for treatment of melanoma.

Authors:  Melissa A Tran; Rebecca J Watts; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-22       Impact factor: 4.693

7.  Altered endosome biogenesis in prostate cancer has biomarker potential.

Authors:  Ian R D Johnson; Emma J Parkinson-Lawrence; Tetyana Shandala; Roberto Weigert; Lisa M Butler; Doug A Brooks
Journal:  Mol Cancer Res       Date:  2014-07-30       Impact factor: 5.852

8.  Radiation improves gene delivery by a novel transferrin-lipoplex nanoparticle selectively in cancer cells.

Authors:  R A Abela; J Qian; L Xu; T S Lawrence; M Zhang
Journal:  Cancer Gene Ther       Date:  2008-05-16       Impact factor: 5.987

9.  Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastases.

Authors:  Matthew Freedman; Esther H Chang; Qi Zhou; Kathleen F Pirollo
Journal:  Acad Radiol       Date:  2009-05       Impact factor: 3.173

10.  Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.

Authors:  Keisuke Fukuchi; Sebastian C J Steiniger; Elena Deryugina; Ying Liu; Colin A Lowery; Christian Gloeckner; Bin Zhou; Gunnar F Kaufmann; James P Quigley; Kim D Janda
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.